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Abstract
Osteoarthritis (OA) is the predominant cause of lameness in horses. As in 
humans, the clinical symptoms of equine OA are persistent pain and dysfunction of 
the affected joint. Its pathology is similarly marked by progressive deterioration of 
the articular cartilage, subchondral bone sclerosis, marginal osteophytes, soft tissue 
inflammation and joint effusion. Disease pathogenesis is mediated by elevated 
levels of inflammatory cytokines and proteolytic enzymes in the articular tissues 
and synovial fluid. Existing pharmacologic agents can alleviate OA joint pain; none 
are able to inhibit erosive disease progression. As several gene-based treatments 
for human disease have received approval by the Food and Drug Administration 
(FDA), the transition to veterinary medicine will almost certainly follow. Several 
viral vector systems have demonstrated highly efficient gene transfer to the equine 
joint, enabling expression of therapeutic transgenes at efficacious levels for well 
over a year. Because of its large size, the equine joint is well suited to studies of gene-
based therapies for arthritic disease. The forelimb joints are vulnerable to OA onset, 
and treatment and diagnostic modalities are the same in humans and horses. Here, 
we discuss the various gene-transfer approaches under investigation and the current 
progress toward the development an effective gene therapy for equine OA.
Keywords: osteoarthritis, lameness, interleukin-1, IL-1Ra, gene therapy,  
adeno-associated virus
1. Introduction
Osteoarthritis (OA) is a chronic, painful, degenerative, often debilitating condi-
tion common in weight-bearing joints of both humans and horses. In humans the 
knees and hips are predominately affected, while in the horse the metacarpophalan-
geal and carpal joints of the forelimb are the primary sites of onset. In both species, 
the pathology of OA is marked by the gradual, persistent erosion of the articular 
cartilage, development of osteophytes at the joint margins, sclerotic growth of 
subchondral bone, synovitis and joint effusion [1]. Biochemical analyses reveal that 
the signaling molecules and pathways that drive the inflammatory and degenerative 
processes in both species are identical [2]. OA is incurable, difficult to manage and 
often progresses to disabling joint failure. It is estimated that over 50 million people 
in the US alone have symptomatic OA. Spontaneous joint disease is a common 
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clinical problem in the horse as well where it is estimated that OA accounts for up to 
60% of lameness [3], and is among the leading causes of debilitation and wastage of 
athletic horses. As with humans, the need for an effective treatment for equine OA 
is immense.
In this chapter we describe progress with an experimental gene-based therapy 
for OA in parallel development for both humans and horses. The concept of a 
genetic therapy was initially put forth as a method to replace defective genes and 
associated protein deficiencies from monogenic diseases, such as cystic fibrosis, 
severe combined immunodeficiency and hemophilia. In the present application 
direct intra-articular gene transfer is used as an improved system for sustained local 
delivery of biologic agents with anti-arthritic potential [4]. By providing for high-
level, persistent production of therapeutic gene products in chronically diseased 
joints, long-standing obstacles impeding effective drug delivery are overcome to 
provide stable production of gene products with activities capable of inhibiting 
not only pain and inflammation, but also the progression underlying the degenera-
tive process. We discuss various approaches for intra-articular gene delivery and 
promising gene products. We also discuss progress toward clinical application and 
remaining challenges.
2. Osteoarthritis pathogenesis
The pathogenesis of OA is complex and can be initiated by a wide range of 
factors. It is most commonly linked with aging and accumulating degradation of the 
cartilage matrix from the loss of cellularity and reduced metabolic activity of the 
chondrocytes [5–7]. In younger individuals, OA most frequently occurs as a second-
ary consequence of joint injury (post-traumatic OA: PTOA) either from repetitive 
trauma to the joint surfaces due to overloading and overuse, or acute damage to the 
structural tissues.
Although cartilage damage and traumatic loading are considered initiating 
factors, a consensus in the literature indicates that inflammatory cross-talk between 
the synovium and cartilage is instrumental in driving the erosive progression of 
OA [8, 9]. Under normal conditions, the chondrocytes, which inhabit the articular 
cartilage at low density, maintain the integrity and quality of the matrix through 
slow continual remodeling through degradation and new matrix protein synthesis. 
Disruption of this homeostasis from chondrocyte dysfunction or depletion from 
apoptosis or necrosis, leads to a reduction in matrix quality, damage to the articular 
surface and pathologic load distribution. The increased compressive forces among 
weight-bearing regions, activates stress signaling pathways in regional chondro-
cytes and a phenotypic shift to an activated phenotype. Stress-induced activation of 
nuclear factor-kappa B (NF-κB), and p38 MAPK and c-Jun N-terminal kinases and 
their downstream signaling cascades halts the synthesis of key extracellular matrix 
(ECM) proteins, stimulates the release of inflammatory cytokines and chemokines 
and expression of matrix metalloproteinases and aggrecanases [1, 10]. The release 
of cellular debris and matrix molecules from eroding cartilage stimulates cytokine 
and toll-like receptors in the synovial lining cells and an inflammatory response in 
the synovium [11, 12]. The resulting synovitis, marked by hyperplasia and hyper-
trophy of synovial fibroblasts, infiltrating macrophages, T cells, and mast cells, is 
a common feature of both early and late-stage disease. Inflammatory activation 
of the synovium stimulates production of enzymes and inflammatory cytokines, 
such as interleukin-1 (IL-1) and tumor necrosis factor α (TNF-α) that feeds back in 
a self-perpetuating cycle to further alter chondrocyte metabolism and the bal-
ance of cartilage matrix synthesis and degradation [9]. With increasing loss of the 
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protective cartilage cushion the increased mechanical forces stimulate a compensa-
tory reaction in the calcified cartilage resulting in increased thickening and stiffness 
of the subchondral bone.
As an avascular tissue, injured cartilage has no mechanism for self-repair or 
regeneration. There is no influx of exogenous cells from ruptured blood vessels to 
generate space-filling tissue. Although local chondrocytes attempt proliferate and 
form chondrocyte clusters in an apparent regenerative, reparative response, the 
dense ECM limits the migration of the limited number of chondrocytes. In cases 
of significant damage, cartilage lesions are essentially permanent and progress to 
fibrillation, formation of fissures, and ultimately complete loss of the cartilage 
surface. Cumulatively, the slow insidious processes cause fibrillation, fissures, 
ulceration and over time the full thickness loss of cartilage and painful bone on 
bone articulation [13].
3. Treatment limitations
Existing medications for OA, such as analgesics and non-steroidal anti-
inflammatory (NSAID) agents are palliative and only provide temporary relief of 
joint pain without significantly altering disease progression or restoring cartilage 
integrity. While there are a variety of biologic agents with activities known to 
inhibit pathologic signaling pathways, due to the unique anatomy and physiology 
of synovial joints, conventional methods of drug delivery are unable to achieve or 
maintain effective concentrations of therapeutic molecules in chronically diseased 
joints [14]. The synovial fluid which serves to lubricate the articulating surfaces and 
nourish the chondroctyes is a dialysate of blood plasma that enters the joint through 
fenestrated capillaries in the subsynovium. This “sieving effect” restricts the entry 
of proteins and other large molecules into the joint space from the circulation [14].
While intra-articular (IA) injection circumvents physical barriers to systemic 
delivery, elevated pressure causes rapid turnover of synovial fluid through the 
lymphatics. Continuous circulation of the synovial fluid causes injected molecules 
to be rapidly cleared from the joint, often with a half-life of less than 4–5 hours, 
depending on the size. Repeated intra-articular injection is not a useful clinically 
as frequent repeated needle sticks are painful, can exacerbate joint pathology and 
carry increased risk of infection [14].
Local intra-articular injection of corticosteroids can provide temporary relief of 
joint pain, but the broad spectrum anti-inflammatory effects are transient. Despite 
the short residence time of intra-articular therapies, studies frequently report 
positive effects from a number of patient-derived preparations, such as platelet rich 
plasma, autologous conditioned serum and various formulations of “mesenchymal 
stem cells” (MSCs). However due to inconsistent methods of preparation and char-
acterization, conflicts of interest and investigator bias, the efficacy of these treat-
ments in both human and equine medicine remains highly controversial. Indeed, 
the assertion that MSCs injected in suspension have an intrinsic capacity to sense 
and address whatever is needed for the repair and regeneration of cartilaginous 
tissue in the joint is not based on scientific evidence [15, 16].
4. OA gene therapy principles
Arthritis gene therapy was conceived as a novel protein-drug delivery system 
capable of exploiting the anti-arthritic properties of endogenous soluble gene 
products for treatment of chronic joint disease [17]. By delivering cDNAs encoding 
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therapeutic products to cells resident in the articular tissues, and providing for high 
levels of independent expression, the biosynthetic machinery of the modified cells 
is directed to overproduce and continuously secrete the transgenic protein into the 
synovial fluid and surrounding tissue. In this manner, the diseased joint becomes 
an endogenous site of sustained, elevated drug production, eliminating the need 
for repeated application, while providing the greatest concentration of the protein 
specifically at the site of disease. While originally envisaged for delivery of secreted 
proteins, similar principles can be applied to gene products that function intracel-
lularly, including transcription factors and interfering RNAs among others. OA 
is an excellent candidate for a local gene-based therapy, as only one or two joints 
are affected in most patients, and there is an absence of significant extra-articular 
disease. Distinct from any existing treatment for OA, this approach has the capacity 
for continuous local delivery of therapeutic molecules that block painful symptoms 
and erosive progression of disease from a single intra-articular injection [4].
The distinct advantage of using a secreted protein is that overproduction from 
a relatively small number of cells can treat the entire joint. While at least in theory, 
gene delivery provides the opportunity to explore the application of cDNAs whose 
products that function intra-cellularly (e.g. transcription factors and interfering 
RNAs), practical application is far more challenging than it may initially appear. In 
order to alter the biology of a diseased tissue, a substantial portion of the cells must 
be modified, requiring extraordinarily high levels of gene transfer in vivo.
A variety of methods can be used deliver therapeutic gene products to joints. 
Once a candidate cDNA is identified, the delivery vehicle that provides efficient 
targeting and modification of the desired cell types in vivo and robust transgene 
expression that persists for a prolonged period of time. For chronic joint diseases, 
such as RA and OA, a minimum of 6 months to a year or more of benefit following 
a single injection would likely be the minimum standard for efficacy. Such a profile 
requires metabolically active target cells with limited turnover [18]. Additionally, 
the vector and genetically modified cells must avoid recognition and elimination 
by the immune system whose central function is to eradicate infectious viruses 
and virally infected cells expressing non-self, surface antigens and stress-induced 
signaling molecules. The immune stealth of the vector, transgene product and 
modified cells are essential for effective gene delivery and prolonged, functional 
transgene expression.
5. Parallel development of gene therapy for human and equine OA
Early preclinical studies showed that local intra-articular delivery of certain 
cDNAs could inhibit experimental arthritis in the joints of laboratory animals. 
Although rodents and rabbits are useful for proof-of-concept studies, their small 
size does not accurately reflect the environment of the human or equine OA joint. 
Following intra-articular injection of a gene delivery vehicle, ensuing patterns of 
transgene expression are dictated by the biophysical interactions between the vector 
and the target tissues. In the case of a recombinant virus for example, dispersion in 
the joint space through the viscous synovial fluid, and its subsequent penetration in 
the ECM of the various tissues, determines the locations, phenotype, number and 
density of the cells that are physically encountered by the vector and genetically 
modified. The composition of the cell population modified by the virus at the time 
of injection, determines the level and duration of therapeutic transgene expression 
-and, in turn, the efficacy of treatment. In this respect, the small joints of a 100–
200 g quadruped rodent cannot duplicate the complex milieu of the knee of a 75 kg 
bipedal human, much less a 500 kg horse. The vastly greater size and internal fluid 
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volume, the differences in cellularity within the dramatically larger and thicker con-
nective tissues, as well as the compressive forces generated during locomotion, have 
a profound influence on the biodistribution of the virus following injection [19].
To model the efficacy of gene delivery in joints of clinically relevant proportions 
and better assess its utility for treatment of OA, the carpal and metacarpophalan-
geal (MCP) joints of the equine forelimb provide highly useful targets. These joints 
are similar in size, function, and tissue composition to the human knee, and since 
they carry 60–65% of the horse’s weight during locomotion, they are highly vulner-
able to OA secondary to trauma and excessive training [2, 3].
Because of its large size, the equine system is particularly well suited for preclini-
cal studies of joint disease. The horse can readily perform controlled exercise, and 
clinical treatment and diagnostic modalities are the same in humans and horses 
[2, 20]. The large joints facilitate joint function analyses, examination of internal 
structures using magnetic resonance imaging (MRI) and radiograph, and minimally 
invasive arthroscopy for visual assessment and biopsy of joint tissues. The capacity 
to aspirate undiluted synovial fluid permits analysis of transgenic protein content 
by enzyme linked immunosorbent assay (ELISA) [21], and since, joint fluids can be 
aspirated serially without adverse effect, patterns of transgenic expression can be 
monitored over time within the same animal.
By examining the efficacy of OA gene therapy in joints of similar proportion to 
the human knee and with similar disease, results representative of the human and 
equine response should be obtainable. Further, the use of the horse as an experi-
mental subject allows practical experience with gene delivery in a relevant context 
and on an appropriate scale. This provides the ability to identify and troubleshoot 
technical and logistical problems in a clinical setting and refine working parameters 
for safety and efficacy prior to entering phase I human or field trials in client horses. 
Moreover, since OA is a significant health issue in both humans and horses, findings 
generated in this system can be applied to both species, allowing the development 
of human and equine medicines in parallel.
6. Ex vivo gene delivery
The initial proof-of-concept was demonstrated using an ex vivo method 
whereby autologous synovial fibroblasts isolated from surgically harvested joint 
tissues, were stably modified with recombinant oncoretroviral vector (Moloney 
murine leukemia virus) to overexpress a secreted IL-1 inhibitor (IL-1Ra) [22, 23]. 
After expansion in culture the cells were injected into the diseased joint where they 
engraft in the synovial lining and continuously secrete the transgene product. This 
method demonstrated the feasibility of intra-articular gene delivery and was used 
successfully in a phase I human trial [24]. However, the procedure proved to be 
labor intensive, time consuming and tedious; its exorbitant cost made the procedure 
impractical for widespread clinical application, especially for a common, non-fatal 
disease.
It is important to note that cell in suspension (regardless the tissue of origin), 
following injected into the joint space, consistently engraft in the synovial lining; 
they do not adhere to or colonize articular cartilage. Cells surgically implanted 
in cartilage defects within a support matrix will remain localized, but lacking a 
method of physical containment loose cells will disperse throughout the capsular 
lining. Along these lines, much has been made in the literature of the anti-arthritic 
potential of so-called “mesenchymal stem cells” or MSCs [15, 16]. These cells are 
amenable to genetic modification and can be used as a vehicle for ex vivo gene 
transfer. However, it is our experience that MSCs in and of themselves are not 
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immune privileged and have no more regenerative or anti-inflammatory value 
than any other cell type injected into the joint. Most investigators have found that 
allogeneic MSCs are cleared very rapidly from the joints of experimental animals, 
with few cells remaining beyond 1–2 weeks.
7. Direct intra-articular gene transfer
Relative to the ex vivo approach, direct injection into the joint of recombinant 
vectors dramatically streamlines the gene delivery procedure [4]. A broad range of 
vector systems, both viral and non-viral have been evaluated for their efficiency 
of gene transfer to the joint tissues in situ [25–30]. While the use of non-viral gene 
delivery vehicles has certain theoretical advantages (larger payload, increased 
perception of safety, straightforward vector production, reduced costs) extensive in 
vivo testing in our laboratory, as well as in others, has shown that non-viral delivery 
of nucleic acids is currently not suitable for treating chronic articular diseases; the 
efficiency of delivery is exceedingly low and typically persists in the joint cells for 
no greater than 2–3 days. While non-viral formulations are often effective transfec-
tion reagents in the context of monolayer cell culture, efficacy in vitro does not 
equate to performance in vivo [31]. Despite claims in the literature regarding the 
treatment of OA, the use of these systems should be avoided as their pharmacoki-
netic profile is incompatible with the pathologic progression of OA.
Similarly, there are dozens of published papers that report remarkable efficacy 
following intra-articular injection of shRNAs, miRNAs, and circRNAs into the 
joints of animals either in suspension or complexed in nano- or micro-particles. As 
mentioned above, for an intracellular approach to be effective in OA, an extraor-
dinarily high efficiency of delivery is required to the cells in target tissues in vivo. 
Moreover as gene expression is an ongoing process, interfering RNAs must be 
maintained at exceptionally high levels in a large proportion of cells and be con-
tinuously replenished to sustain gene silencing. While achievable when delivered 
in an exogenous expression cassette, it is not possible with the delivery of soluble 
or complexed inhibitory RNAs. These reports should be regarded with a healthy 
degree of skepticism.
Viral-based vector systems exploit the natural ability of a virus to deliver its 
genetic payload to a target cell with high efficiency. For the generation of a viral-
based vector system, the coding sequences for viral proteins essential for replication 
are removed from the viral genome and the products are supplied in trans during 
vector propagation in permissive engineered cell lines. Several recombinant viral 
vector systems have shown the capacity to deliver exogenous genes to joint tissues 
and enable expression of therapeutic transgene products at levels sufficient to 
inhibit arthritic pathologies in laboratory animals. Among these are recombinant 
adenovirus [27], herpes simplex virus [28], adeno-associated virus (AAV) [32, 33], 
and lentivirus [29, 34] among others. Each of these systems has inherent advan-
tages and limitations that dictate the applications for which they are best suited. 
Currently only two viral vectors, recombinant adenovirus and AAV, are in serious 
preclinical development for equine or human OA.
7.1 Recombinant adenovirus
First generation recombinant adenovirus provides highly efficient transduction 
of target cells in various connective tissues both in culture and in vivo [25, 26]. 
Several years ago this system was the workhorse vector of the field of musculo-
skeletal gene therapy [35]. Adenoviral vectors showed that the concept of direct 
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intra-articular gene transfer was capable of providing functional levels of transgene 
expression in the joints of animal models. In the first generation vectors the E1 
and E3 genes required for immediate early stage gene expression and initiation of 
viral replication were deleted from the genome to prohibit viral replication in cells 
infected by the vector. Their removal also provided room for the insertion of an 
exogenous expression cassette [36].
The relative ease of production reduced the barrier to entry and provided gene 
transfer technology to any laboratory with basic molecular biology capabilities. 
Although viral replication was crippled in non-permissive cells, the vector still 
retained the majority of the native coding sequences. Leaky expression of viral 
proteins by transduced cells caused them to be eliminated in 2–3 weeks by adaptive 
cellular immune responses [27, 37]. Despite its transient nature, adenoviral gene 
delivery provided a burst of high level transgene expression sufficient to examine 
the biological activity of a specific gene product in vivo. Adenovirus has the reputa-
tion of causing acute toxicity from innate inflammatory responses, but much of 
this is due to low quality, inconsistent vector preparations containing high levels 
of cellular debris. Advances in adenoviral technology include the development of 
helper dependent systems in which the coding sequences for all viral proteins have 
been removed and are supplied during propagation by a second “helper” adenoviral 
vector, which is removed by differential centrifugation during purification [38]. 
These modifications allow for increased immune avoidance and long-term trans-
gene expression without significant reduction in infection efficiency [39–41].
7.2 Adeno-associated virus
Of the well-characterized viral systems, AAV offers many advantages that favor 
its use for the treatment of arthritis: (1) The wild type virus is not associated with 
any pathologic human condition. (2) The recombinant form does not contain native 
viral coding sequences, which reduces its immunogenicity. (3) AAV can infect both 
dividing and quiescent cells. (4) Persistent transgenic expression in vivo has been 
observed in many applications, and (5) the recombinant form does not integrate 
into the genome of the target cell with significant frequency [42].
A further potential advantage is the relative simplicity of the AAV vector, which 
is comprised of an ~5000 nucleotide single-stranded DNA genome packaged in a 
small (20–30 nm), non-enveloped icosahedral particle by three capsid proteins, 
differing only at their N termini [43]. The only required cis elements on the vec-
tor DNA are 145 nucleotide-long inverted terminal repeats (ITRs) that flank the 
transgene expression cassette.
Fortuitously, with regard to veterinary medicine, in head to head comparisons 
equine synovial fibroblasts in culture are significantly more receptive to AAV 
transduction than their human counterparts. Preliminary evidence suggests 
increased expression of surface receptors between the two species in culture. How 
this discrepancy translates to the in vivo situation is unclear, as phase I testing in 
humans has just begun, but transgene expression is robust in equine joints.
Additionally, humans are natural hosts to wild type AAV infection and often 
have high circulating titers of neutralizing antibodies (NAb) to AAV capsids of 
several serotypes (primarily AAV2, AAV1, and to lesser extents AAV5) from prior 
infections with wild type virus. Horses, however, are not common hosts for wild 
type AAV infection, and distinct from humans, have low circulating NAb titers 
to most AAV vector serotypes. While NAb to AAV5 appears relatively frequently 
among horses, and one report describes increased NAb titers to AAV2 capsid in 
a small test sample, pre-existing NAb do not appear to be prevalent in the equine 
population nor at sufficient titer to prohibit effective gene delivery [44, 45].
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Typically, following intra-articular injection of a recombinant virus, the over-
whelming majority of genetically modified cells are found in the synovium, sub-
synovium and supporting capsular and ligamentous tissues. Chondrocytes, while 
receptive to genetic modification in culture, are not efficiently transduced in vivo 
due to the inability of most vector particles to effectively penetrate the dense carti-
lage ECM. The only exception is AAV whose small particle size permits its entry and 
diffusion through the dense cartilage ECM enabling interaction and transduction 
of chondrocytes deep within the cartilage. As chondrocyte dysfunction and carti-
lage degeneration are the characteristic pathologies of OA, the capacity to deliver 
therapeutic genes to chondrocytes is a clear advantage to this vector technology. 
Moreover, since these cells are highly stable, their modification with AAV provides 
the prospect of enduring transgenic expression [46].
8. Therapeutic strategies
Two complementary gene-based strategies have been investigated for OA. The 
first is geared toward chondroprotection, and involves delivery of gene products 
that enhance joint lubrication or block the activities of specific inflammatory 
cytokines that stimulate inflammation and the subsequent degeneration of cartilage 
ECM by articular chondrocytes [47–49]. Most studies of OA gene therapy have 
involved the delivery of the cDNA for interleukin-1 receptor antagonist (IL-1Ra) a 
competitive inhibitor of IL-1 signaling [50–55].
The second strategy is directed toward cartilage repair or regeneration using 
various anabolic, proliferative or chondrogenic agents to stimulate regional chon-
drocytes to proliferate and elaborate cartilage ECM. While these strategies appear 
attractive at the outset, unfortunately, as vectors (and cells) injected into the joint 
primarily interact with synovial fibroblasts, many growth factors that may stimu-
late cartilage repair or matrix synthesis by chondrocytes will likewise stimulate the 
abundant fibroblast populations in the synovium to generate undesirable, often 
dramatic adverse side effects. For example, intra-articular delivery of adenovirus 
containing the cDNA for TGF-β1 induces an extraordinarily potent fibrotic, chon-
dro-osseous response in the synovium and joint capsule [56, 57]. Systemic patholo-
gies such as pulmonary fibrosis in rats and death in rabbits occurred when TGF-β1 
was expressed intra-articularly at high levels. Overexpression of TGF-β1 and BMP-2 
has also been shown to induce the formation of osteophytes, ectopic cartilage and 
bone formation [56, 58]. Of the growth factor genes tested thus far, only IGF-1 has 
not been associated with an overt pathologic response [45, 59], but it has not been 
evaluated extensively. Concerns over potential side effects have generally limited 
the use of growth factor genes to localized applications in tissue engineering for 
cartilage repair, whereby chondrocytes or MSCs are modified in culture to express 
a specific growth factor before surgical implantation into focal cartilage lesions, In 
this manner, the expressed protein is localized to the defect, reducing exposure to 
adjacent tissues.
8.1 Interleukin-1 receptor antagonist
A consensus in the literature indicates that IL-1, synthesized locally by chon-
drocytes and synovial cells, is instrumental in driving OA progression [60, 61]. 
Found at increased levels in OA joints, IL-1 is the most potent physiological inducer 
of chondrocytic chondrolysis (the major route to cartilage loss in OA) [62]. Even at 
trace levels, IL-1 strongly inhibits ECM production in cartilage by blocking col-
lagen type II and proteoglycan synthesis and enhancing chondrocyte apoptosis. At 
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slightly higher concentrations proteolytic enzyme synthesis is induced in chon-
drocytes, driving enhanced production of matrix metalloproteinases (MMPs) and 
aggrecanases that degrade the cartilaginous matrix [63]. As a primary mediator of 
the inflammatory cascade, IL-1 stimulates articular cells to produce a full comple-
ment of OA effector molecules, including cyclooxygenases I and II, nitric oxide, 
phospholipase A2, prostaglandin E2, reactive oxygen species as well as inflammatory 
cytokines and chemokines. Release of these molecules further stimulates cartilage 
matrix degradation, bone erosion, synovitis and fibrosis. IL-1 is also suspected to 
mediate pain in OA, the most common reason for consulting a physician [64–67].
Traditional pharmacologic approaches have failed to produce clinically useful 
molecules for inhibiting IL-1 activity intra-articularly [68]. However, two naturally 
occurring proteins exist specifically for this purpose: IL-1Ra and the soluble IL-1 
type II receptor (sIL-1RII) [69, 70]. IL-1Ra functions as a competitive inhibitor by 
binding to the type I IL-1 signaling receptor and preventing subsequent interac-
tion with IL-1. Once bound, IL-1Ra fails to recruit the IL-1R accessory protein 
(IL-1-AcP) to the complex and prevents intracellular activation and signaling. The 
sIL-1RII molecule, in contrast, titrates IL-1 activity by binding directly to soluble 
IL-1 molecules and blocking interaction with the type I receptor [71, 72]. Despite 
differences in their modes of action, the two molecules inhibit IL-1 signaling with 
equal potency. In the context of gene therapy, IL-1Ra is a smaller protein and easier 
to express as a transgene product. The recombinant protein (anakinra/Kineret®) 
is well characterized and is approved for clinical use in humans for RA and other 
conditions in which IL-1 is known to pay a significant role [71, 72]. As anakinra 
is administered daily by subcutaneous injections of 150 mg, the risk of adverse 
response from overproduction intra-articularly is extremely small.
Commercially available ELISAs with specificity for IL-1Ra orthologs in human, 
mouse and horse permit sensitive quantitation in culture media and biological 
fluids. Analysis of synovial fluid permits the use of IL-1Ra as a quantitative reporter 
of total gene transfer and therapeutic gene expression, allowing direct comparison 
of various delivery platforms. With respect to OA, IL-1Ra does not require sophis-
ticated regulation. The goal is simply to express IL-1Ra at levels 10–100 fold over 
IL-1, where it completely inhibits IL-1 signaling activity. Once the threshold for 
efficacy has been achieved, expression beyond this has no adverse effect [73].
It is possible that a dual therapy combining elements of chondroprotection and 
regeneration could both inhibit degeneration and stimulate cartilage repair [48, 74]. 
Such a strategy, though, would likely require gene delivery via separate vectors to 
account for differences in their expression patterns for safe, effective application.
9. Preclinical studies
Following a series of preclinical successes in small laboratory animals dem-
onstrating the proof of concept for direct viral-mediated gene delivery to joints, 
studies were performed to evaluate direct viral mediated gene delivery to equine 
joints using a first-generation adenoviral vector containing the cDNA for equine 
IL-1Ra. Administration of Ad.eqIL-1Ra in the joints of healthy horses, produced 
dose-dependent increases in IL-1Ra levels in synovial fluid aspirates. However, 
the highest viral dose tested, 5 × 1011 viral particles (vp) produced an acute 
synovitis [21].
To explore the capacity of Ad.eqIL-1Ra to inhibit OA pathologies, an osteo-
chondral fragment (OCF) model of OA was used [21, 75]. In this system, a small 
osteochondral chip is surgically generated off the distal radial carpal bone of the 
midcarpal joint. Following a brief interval to recover from surgery, animals in the 
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treatment group are injected in the OCF joint with the vector, while control animals 
receive saline [21]. The horses are then exercised 5 days/week on a high-speed 
treadmill, which, in the context of the osteochondral fracture, generates predictable 
pathologic lesions that mimic the onset of equine disease [21]. ELISA analysis of 
joint aspirates showed a peak in eqIL-1Ra expression at 7 days post injection which 
gradually diminished over a period of 28 days. Clinical examinations indicated 
that the expression of IL-1Ra decreased joint pain and synovial effusion relative to 
untreated horses, and protected the cartilage from the loss of proteoglycans.
These findings provided strong support for local gene delivery of IL-1Ra in large 
mammalian joints. A central limitation, however, was the use of the first generation 
adenovirus. In later work, we found articular tissues to be highly immune sensitive 
to the expression of foreign proteins, such that cells expressing foreign non-homol-
ogous transgene products or viral proteins are recognized by cell-mediated immune 
responses which lead to abbreviated persistence of transgenic expression in vivo 
[37]. Thus while the results showed promise, they indicated an intense need for an 
improved, immune stealthy vector system.
9.1 AAV-mediated gene delivery to equine joints
The results of studies of other gene therapy applications, such as hemophilia, 
indicated that long-term transgene expression was achievable following direct 
delivery of AAV vectors. The results of exploratory experiments in joints were 
disappointing. Transgene expression from conventional single-strand AAV vectors 
required several days or weeks to onset with marginal levels of protein production 
intra-articularly, a pattern that prevented testing in experimental disease models.
AAV transduction efficiency is known to be enhanced by mechanisms associ-
ated with intracellular stress. Certain stimuli, such as UV radiation, which increase 
the production of DNA synthesis and repair enzymes, significantly enhance 
intra-articular transgene expression from conventional AAV vectors [33, 76, 77], 
which indicates that second strand DNA synthesis is rate-limiting in joint tissues. 
Accordingly, AAV vectors that are self-complementary (sc) (i.e. double stranded, 
containing both + and – DNA strands) generated through the use of half-genome 
sized vector plasmids, or those containing a mutation in one of the terminal resolu-
tion sequences of the AAV ITRs [78, 79], provided ~20-fold enhancement of gene 
expression, with rapid onset in synovial and capsular cells in vitro and in vivo 
[80]. This adaptation was found to provide transduction and transgene expression 
profiles comparable to that provided by adenovirus. The requirement for a half-
sized genome, however, limits the size of the transgene to about 1000–1200 base 
pairs [79].
Following encouraging results with scAAV vectors in the joints of laboratory 
animals [80], studies of AAV gene transfer shifted to the equine model to assess 
more clearly its utility for therapeutic gene delivery in large OA joints [19, 81]. As 
before, the carpal and MCP joints of the equine forelimbs were targeted for injec-
tion. In pilot studies, AAV gene delivery to healthy joints was examined using vec-
tors containing the cDNAs for human IL-1Ra (AAV.hIL-Ra) and green fluorescent 
protein (AAV.GFP) [19]. In the animals receiving AAV.hIL-1Ra, synovial fluids were 
aspirated periodically over a period of several weeks. Animals receiving AAV.GFP 
were euthanized 14 days after injection and the distribution of fluorescence in the 
joint tissues was used to determine the number and locations of the cells modified 
by the AAV virus following intra-articular injection.
AAV gene delivery in the equine joints was capable of elevating the steady state 
hIL-1Ra in synovial fluid to levels equivalent to or greater than observed previously 
in rodents [19]. Analysis of GFP fluorescence showed that the vast majority of the 
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transgene expression originated from the fibroblasts resident in the synovial lining. 
Fluorescent cells in the articular cartilage, though visible, were sparse, and GFP 
expression was faint. Peak levels of hIL-1Ra occurred at 1–2 weeks post-injection, 
but steadily declined over a period of 5 weeks. Studies in nude rats indicated that 
the abbreviated transgene expression was due to immune elimination of the cells 
expressing the xenogeneic human IL-1Ra protein [37].
9.2 Codon optimization of the equine IL-1Ra cDNA
The commercial release (R&D Systems, Minneapolis, MN) of an ELISA kit 
specific for the equine IL-1Ra ortholog in 2010 proved to an enabling technology, 
allowing for the first time definitive quantification of the equine transgene intra-
articularly [82]. Prior to this point, expression data relied on inter-species cross-
reactivity between human and murine ELISAs, results which were inconsistent and 
highly error prone.
To examine AAV-mediated transgene expression in the absence of immune 
interference, the human cDNA was replaced with the homologous equine IL-1Ra. 
To overcome initial problems with low production levels, codon-optimization 
resulted in >50-fold amplification in IL-1Ra secretion [18, 82]. For use in safety 
studies for the FDA, the cDNAs for human and rat IL-1Ra were also codon-opti-
mized using the same algorithm [55]. After packaging in the AAV capsid, infection 
of synovial fibroblast cultures over a range of doses generated exceptionally high 
levels of IL-1Ra protein in conditioned medium, which exceeded 10 µg/ml at a vec-
tor dose of 105 vg/cell [18].
Using the optimized AAV.eqIL-1Ra vector, a series of pharmacokinetic studies 
were performed to establish vector dose expression profiles following intra-articular 
injection [18]. In each of six horses, the midcarpal and MCP joints of both forelimbs 
were injected with AAV.eqIL-1Ra at doses ranging from 5 × 1010 to 5 × 1012 vg; the 
remaining joint received an equivalent volume of saline and served as a negative 
control. Analysis of synovial fluid, peripheral blood and urine collected periodically 
over a period of 6 months showed dose-related increases in the eqIL-1Ra content in 
synovial fluid at 2 weeks of injection, with peak production between 4 and 8 weeks. 
At the highest vector dose synovial fluid IL-1Ra levels exceeded 40 ng/ml, ~400-
fold higher than endogenous synthesis. Importantly IL-1Ra production remained at 
these levels for the duration of the 6-month study. Despite simultaneous injection of 
recombinant AAV in three forelimb joints, no adverse effects were observed. IL-1Ra 
in blood serum, urine and synovial fluid of control joints remained at pre-injection 
levels (<100 pg/ml) throughout [18].
9.3 AAV gene delivery in naturally occurring OA
As discussed previously, the pathologic progression of OA induces sweeping 
changes in the architecture, cellularity and activation of the articular tissues. 
In conjunction with vector dosing, a series of tracking studies were performed 
to examine the impact of the OA environment on transgene expression and the 
biodistribution of the vector DNA and transduced cells [18]. Using a dose of 5 × 
1012 vg, AAV.GFP was injected into one forelimb joint of several healthy horses, and 
horses with advanced naturally-occurring OA. Analysis of tissue samples 2 weeks 
later showed GFP fluorescence in healthy joints was concentrated in the synovial 
lining, with only a handful of GFP+ cells visible in cartilage shavings (Figure 1). In 
joints with advanced OA, there was a striking increase in GFP expression in all joint 
tissues particularly in articular cartilage. In synovium, enhanced GFP expression 
was due to the increased cellularity from local inflammation. Although fluorescence 
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was greater in all cartilage shavings, GFP expression in regions containing visibly 
damaged cartilage was markedly increased. GFP+ chondrocytes appeared through-
out the damaged regions, particularly in clusters of proliferating chondrocytes, 
characteristic of OA cartilage.
In both healthy and OA joints receiving virus, no GFP+ cells were detected in 
extra-articular tissues, and qPCR analyses showed that 99.7% of the vector DNA 
was localized within the cartilage and synovium of the injected joint. Similar 
patterns of biodistribution were noted by Goodrich et al. [81]. While the enhanced 
transduction of OA chondrocytes might be presumed to arise from increased vector 
access from ECM degradation, qPCR analyses showed the vector DNA content in 
the chondrocytes of healthy and OA cartilage was essentially the same, suggesting 
that the increased transgene expression arose from increased metabolism due to 
inflammatory and stress induced activation [18].
Transcription from the CMV immediate early promoter, which drives the scAAV 
vector expression cassette, is induced in response to NF-κB activation and signal 
transduction from p38 and other stress-activated protein kinases. Similar stress-
related induction of this promoter serves to re-activate human CMV from latency, 
and is required for expression of genes necessary for DNA replication [83–87]. In 
the same manner, inflammation and cellular stress can significantly increase the 
transcription and expression of transgenes under control of the CMV immediate 
early promoter [87–90]. In these respects, OA cartilage is highly enriched with 
stress-activated chondrocytes [91], especially at sites of cartilage degradation, 
where GFP expression was greatest.
Although several reports describe the generation of synthetic inflammation-
inducible promoter systems for gene therapy applications, the AAV vector discussed 
here, at least within the context of a large mammalian joint, appears to be highly 
responsive to the OA environment and innately disease activated. The regional 
Figure 1. 
Representative fluorescence activity in synovium (top row) and cartilage (bottom row) following intra-
articular injection of an AAV vector containing the cDNA for green fluorescent protein (GFP) into healthy 
carpal joints or those with naturally-occurring OA.
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differences in GFP expression seen in OA cartilage indicate the potential to direct 
therapeutic transgene expression preferentially to areas of articular cartilage under 
the greatest pathologic stress. This perhaps lays the groundwork for develop-
ment of vectors for disease-targeted anabolic stimulation of cartilage repair and 
regeneration.
9.4 AAV.eqIL-1Ra delivery and expression in the OCF model
The OCF model was adapted to determine if the levels of equine IL-1Ra gen-
erated by AAV gene transfer were sufficient to mediate an appropriate biologic 
response [92]. Following creation of the osteochondral fracture, the OCF joints in 
the treated animals were injected with 5 × 1012 vg AAV.eqIL-1Ra, while controls ani-
mals received an equal volume of saline. One week later the animals were placed on 
a 5 day/week athletic training protocol for a period of 10 weeks. In this acute injury 
model, mean eqIL-1Ra expression was initially ~4-fold higher than observed in 
healthy joints at the same viral dose and correlated directly with the severity of joint 
pathology at the time of vector delivery. Over the 10 week training period, eqIL-1Ra 
expression gradually diminished to ~60 ng/ml, similar to that seen with AAV gene 
transfer in normal joints. Despite variable expression among animals the steady-
state eqIL-1Ra in synovial fluids exceeded that of IL-1 by >500-fold in all animals. 
In agreement with increased IL-1Ra, the treated horses showed a reduction synovial 
fluid PGE2 levels and a progressive reduction in joint pain. Improved joint function 
was accompanied by significant reduction in joint pathology by both arthroscopy 
and MRI. By both diagnostics, the treated animals showed significant reductions in 
synovial effusion and marrow edema, local protection of cartilage and enhanced 
repair of the osteochondral fragment [92].
Consistent with the findings of others [45, 93], we observed an increase in AAV 
capsid-specific neutralizing antibody (NAb) titer over time in both the blood serum 
and synovial fluid of the horses receiving the AAV vector [92]. The NAb titer in 
synovial fluids was consistently several-fold higher than in blood but had no obvi-
ous effect on transgene expression.
Humans are natural hosts to wild type AAV infection and often have high 
circulating titers of neutralizing antibodies (NAb) to AAV capsids of several 
serotypes (primarily AAV2, AAV1, and to lesser extents AAV5) from prior infec-
tions with wild type virus. Horses, however, are not common hosts for wild type 
AAV infection and distinct from humans, have low circulating titers to most AAV 
vector serotypes. While NAb to AAV5 appears to be relatively common among 
horses, and one report describes increased NAb titers to AAV2 capsid in a small test 
sample, pre-existing NAb do not appear to be prevalent in the equine population 
nor at sufficient titer to prohibit effective gene delivery. As indicated above, high 
levels of capsid serotype specific NAb will arise from prior treatment with an AAV 
vector, which can inhibit the efficacy of subsequent vector administration. There is 
evidence that vector neutralization can be averted through the use of an alternate 
capsid serotype.
9.5 Long-term efficacy
The primary advantage of a gene-based therapy for OA lies with the capacity for 
sustained local delivery of anti-arthritic agents and the promise long term thera-
peutic benefit. To address this, we recently completed a series of studies to assess 
the safety and efficacy of AAV.eqIL-1Ra delivery in a chronic model of joint disease 
over the course of a year. For the chronic model, the 10 weeks OCF protocol was 
used to induce joint pathology consistent with early symptomatic disease. At the 
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completion of the athletic training period, 5 × 1012 vg of the AAV.eqIL-1Ra vector 
was injected into the OCF joint, and a 3 day/week training regimen was insti-
tuted to maintain a slow but progressive degenerative condition for the following 
12 months.
Immediately prior to injection, and then at 2 weeks and monthly thereafter, 
peripheral blood, urine and synovial fluids were collected, and joint pain and 
kinematic assessments were performed. Radiographic and MR imaging of both 
midcarpal joints was performed prior to injection and then at 6- and 12-month 
time points. Arthroscopic examination of the joints was performed at endpoint 
and digitally recorded, and synovial and articular cartilage biopsies were taken for 
histologic examination. At the conclusion of the year-long protocol all animals in 
the treatment group and five animals from the Control group were euthanized for 
biodistribution and toxicology analysis.
Analysis of synovial fluids showed that high IL-1Ra levels of 40–50 ng/ml were 
sustained over the 12-month course of the study. In the chronic OCF model trans-
genic IL-1Ra expression was far more consistent among individual animals than 
in joints with an acute osteochondral fracture. Relative to arthritic controls, the 
treated animals showed a ~40% reduction in lameness, indicative of reduced joint 
pain and improved mobility. By MRI assessment, joint pathology in the was reduced 
by ~28% relative to baseline disease, while in control joints the overall pathology 
was largely unchanged. Relative to pretreatment levels the treated group showed 
~28% improvement in all major OA pathologies relative to baseline while in arthritic 
controls pathologic scores remained unchanged or increased in severity.
9.6 Toxicology and biodistribution
To establish a qualified biosafety profile for AAV.IL-1Ra gene transfer in a large 
mammalian joint, formal preclinical toxicology and biodistribution studies were 
performed addressing the acute and long-term phases of vector delivery. In the Acute 
Phase studies, early stage disease was induced in one midcarpal joint using the OCF 
protocol. Three horses each were injected with 5 × 1012 vg AAV.eqIL-1Ra, 1× anticipated 
clinical dose, and three horses with 5 × 1013, 10× clinical dose, intended to represent 
a “worst case scenario.” For the long-term toxicology studies, each of the 10 horses 
from the treated group in the 12-month study and 5 horses randomly selected from the 
control group were euthanized for necropsy. Following euthanasia, samples from more 
than 50 tissues were collected for histopathologic evaluation or DNA extraction and 
PCR analysis of vector genome content.
In all animals injected with AAV.eqIL-1Ra at the 1× dose, high vector genome 
copies (104–106) were detected by qPCR in the synovium and cartilage, which were 
equivalent in animals euthanized at 2 weeks and 12 months post-injection. No vec-
tor DNA was detected in extra-articular tissues. No pathologic response associated 
with vector injection was observed in any tissue.
The cumulative data from these pharmacokinetic, toxicology and efficacy stud-
ies in the equine model demonstrate that a gene-based therapy using recombinant 
AAV can provide safe, long-term, effective delivery of anti-arthritic proteins, such 
as IL-1Ra, in large mammalian joints. The results of these safety and efficacy studies 
in horses formed the bases for a successful IND application and the initiation of a 
phase I trial of AAV-IL-1Ra delivery for knee OA.
9.7 Gene delivery with high-capacity adenovirus
Recently, studies involving gene delivery with HD.Ad have begun to move 
toward clinical studies, at least in human OA. Initial studies in mice using 
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intra-articular HD.Ad-mediated delivery of the cDNA for lubricin (Prg4) showed 
a marked chondroprotective effect, maintaining matrix volume and prevention of 
degeneration in a cruciate ligament transection (CLT) PTOA model [39].
Progressing from these results, studies were performed to examine the thera-
peutic capacity of IL-1Ra gene delivery via HD.Ad in mice and the forelimb joints 
of horses [94]. In most gene therapy applications a strong, constitutively active 
promoter sequence, such as the CMV promoter/enhancer or the eukaryotic transla-
tion initiation factor 1α (EIF-1α) promoter is used. In this case, however, transgene 
expression was driven by an inflammation-inducible promoter comprised of a 
minimal endothelial cell leukocyte adhesion molecule (ELAM1) promoter linked to 
multiple upstream NF-κB recognition elements. The rationale being that therapeu-
tic transgene expression would be delimited specifically to inflammatory flares.
Similar to prior studies with Prg4, HD.Ad delivery of the homologous murine 
IL-1Ra transgene was found to inhibit osteophyte formation and cartilage erosion 
in the CLT defect model [94]. Importantly, vector delivery was also associated with 
a significant reduction in pain sensitivity. Following preliminary dosing studies in 
healthy equine joints, HD.Ad was used to deliver the eqIL-1Ra cDNA into the carpal 
joints of horses following surgical generation of the osteochondral lesion in the OCF 
model. IL-1Ra levels in the injected joints rose to ~20 ng/ml within the first week, 
but then dropped about 10 fold by week 2 and were near endogenous background 
by week 3. Despite the relative brevity of expression, the treated animals showed 
significant improvement in lameness, reduced joint effusion, synovitis and osteo-
cyte formation and improved cartilage matrix integrity [94].
Due its relatively large size, the adenoviral particle cannot penetrate the ECM 
of the synovium or cartilage and remains constrained to cells residing in super-
ficial regions [39]. Interestingly in both reports where intra-articular transgene 
expression was quantified, a 90–99% loss in therapeutic transgene expression was 
observed within 1–2 weeks of vector injection, regardless of whether an inducible 
promoter was used [39, 94]. While transgene expression seems to persist long-term, 
therapeutic protein levels appear at trace levels. Given this profile, it will be inter-
esting to see how this platform moves ahead in the future.
10. Conclusions
These data altogether show that in large mammalian joints, local gene transfer 
can provide persistent IL-1Ra transgene expression at therapeutically relevant 
levels. Despite variable expression among treated joints in the context of acute 
inflammation, sustained IL-1Ra expression provides meaningful benefit, such that 
a single injection reduces joint pain and intra-articular inflammation, and improves 
repair of the damaged bone and protects cartilage against degradation. No adverse 
response to the vectors or transgene have been observed with either AAV or HD.Ad, 
and at least within the equine system local overexpression of IL-1Ra provides no 
apparent risk of systemic immunosuppression.
Having established safety and efficacy of IL-1Ra gene delivery in the equine 
joint, the next stage in development would be the move into field testing with client 
animals. Given the limited resources available for equine research, such a large 
and costly undertaking is likely feasible only through support from partners in the 
veterinary pharmaceutical industry or private investors looking to advance the 
treatment methods toward commercialization. In this respect, questions of market 
size, cost of goods and profitability move to the forefront. Currently human gene-
based therapies come with a substantial price tag, and range at the high end from 
$450,000 per eye for Luxterna® for congenital retinal degeneration to $2,100,000 
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for Zolgensma®, a gene correction therapy for spinal muscular atrophy in infants. 
Both of these “drugs” employ AAV as a vector. As the popularity of gene-based 
therapies continues to advance, production costs will likely fall considerably as 
the field grows and therapies with greater efficacy emerge. Among these business 
issues, questions regarding genetic enhancement in the racing industry will need to 
be addressed and resolved.
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